Study examines changes in the vitamin D receptor gene in 200 people with MS Written by Steve Bryson, PhD | Oct. 21, 2026 Certain variants in the vitamin D receptor gene were linked to motor symptoms and spinal cord lesions in people with multiple…
The first disease-modifying drugs for Alzheimer’s disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments. Research…
by BARBARA MORSE, NBC10 (WJAR) — In the last three years, the FDA has approved two disease-modifying drugs for those with early stage Alzheimer's disease. And a third drug to treat some of the associated symptoms. Then, we hear about what's called…
Race and ethnicity are tied to who receives antiamyloid drugs for mild cognitive impairment and dementia, even after adjusting for neighborhood vulnerability, a study shows. Disparities in Antiamyloid Medication Access for MCI and Dementia Among patients with mild cognitive impairment…
A MAJOR UK trial will test whether medicines already used for diabetes and attention deficit hyperactivity disorder (ADHD) could help slow the progression of Alzheimer’s disease. The Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial (AD-SMART) will assess several potential treatments…
A UK trial that will test several potential Alzheimer’s disease treatments at the same time has launched, with organisers saying its design could cut years from the search for effective therapies. The Alzheimer’s disease Systematic Multi-arm Adaptive Randomised Trial (AD-SMART),…
The children were recruited at Nationwide Children’s Hospital in Columbus, Ohio, between 2012 and 2017. In the fully blinded, parallel-group trial, the intervention group received daily dissolvable powder containing 200 mg of DHA from algal oil and 200 mg of AA from fungal oil…
Sandusky Register Alzheimer's disease has touched the lives of millions Tens of millions of people have Alzheimer's disease worldwide, accounting for 60 percent to 70 percent of the total number of people living with dementia globally, according to the World Health Organization…
A 36-month retrospective study associated donepezil with early, short-lived brain-network gains but continued cognitive decline and left-hippocampal atrophy in Alzheimer’s-related mild cognitive impairment. Donepezil-linked network gains fade as cognition and hippocampus decline Its retrospective, single-arm design and small longitudinal cohort…
A meta-analysis of 37 real-world lecanemab studies found ARIA in 15.1% of cases, with higher rates among APOE ε4 homozygotes and people with baseline microhemorrhages, but insufficient controlled evidence to confirm cognitive efficacy. Subject of Research: Real-world safety and clinical evidence for lecanemab…
Routes, delays, expansions and everything at the airport.
An article joins this feed when it matches these terms. Each one is also a search of its own.